Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

ClinicalTrials.gov ID: NCT00044577

Public ClinicalTrials.gov record NCT00044577. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 12, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

See Detailed Description

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA-approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.

Study identification

NCT ID
NCT00044577
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
ViiV Healthcare
Industry
Enrollment
166 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 15, 2002
Primary completion
May 24, 2004
Completion
May 24, 2004
Last update posted
Mar 23, 2020

2002 – 2004

United States locations

U.S. sites
30
U.S. states
14
U.S. cities
23
Facility City State ZIP Site status
GSK Investigational Site Los Angeles California 90046
GSK Investigational Site Oakland California 94602
GSK Investigational Site Fort Lauderdale Florida 33145
GSK Investigational Site Fort Lauderdale Florida 33308
GSK Investigational Site Fort Lauderdale Florida 33316
GSK Investigational Site Fort Myers Florida 33901
GSK Investigational Site Jacksonville Florida 32206
GSK Investigational Site Miami Beach Florida 33140
GSK Investigational Site Orlando Florida 32804
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Plantation Florida 33317
GSK Investigational Site Tampa Florida 33602
GSK Investigational Site Atlanta Georgia 30308/30309
GSK Investigational Site Atlanta Georgia 30308
GSK Investigational Site Atlanta Georgia 30339
GSK Investigational Site Augusta Georgia 30912
GSK Investigational Site Indianapolis Indiana 46202
GSK Investigational Site New Orleans Louisiana 70115
GSK Investigational Site St Louis Missouri 63108
GSK Investigational Site Stony Brook New York 11794
GSK Investigational Site The Bronx New York 10468
GSK Investigational Site Charlotte North Carolina 28209
GSK Investigational Site Akron Ohio 44304
GSK Investigational Site Philadelphia Pennsylvania 19102
GSK Investigational Site Philadelphia Pennsylvania 19131
GSK Investigational Site Columbia South Carolina 29206-4713
GSK Investigational Site Dallas Texas 75204
GSK Investigational Site Dallas Texas 75208
GSK Investigational Site Hampton Virginia 23666
GSK Investigational Site Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00044577, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 23, 2020 · Synced Sep 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00044577 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →